• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Maribavir safety and efficacy for cytomegalovirus infections among transplant recipients

byShani ChibberandRavi Shah, MD MBA
October 11, 2019
in Chronic Disease, Infectious Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. This phase 2, parallel-group randomized control trial compared the safety and efficacy profile of maribavir versus valgancicvlovir among patients who received solid organ transplants, finding that both medications had comparable efficacy profiles in preventing CMV infection within 6 weeks of starting therapy.

2. Patients randomized to receive maribavir had a higher incidence of adverse events, with the most common adverse event noted to be dysgeusia and gastrointestinal-related symptoms.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Cytomegalovirus (CMV) infection is a potential concern among patients who have undergone solid organ transplantation. Current medications that are approved to prevent or treat CMV infection have toxic side effects such as myelosuppression, nephrotoxicity and electrolyte imbalances. Maribavir, a selective benzimidazole riboside, is a new medication that is being studied as a potential treatment for CMV infection prophylaxis. Maribavir prevents the exit of viral capsids from the cell nucleus by inhibiting CMV protein kinase UL97. In this phase 2 analysis, researchers compared the safety and efficacy profile of maribavir as compared to valganciclovir among patients who had received hematopoetic-cell or solid organ transplantation. Overall, researchers found that both regimens had similar efficacies in treating and preventing CMV infection. Patients randomized to receive maribavir had a higher incidence of gastrointestinal-related adverse events including dysgeusia. Patients randomized to receive valganciclovir had a higher incidence of neutropenia during the study period. Overall this study indicates that more research is warranted to evaluate maribavir and its treatment efficacy for this patient population.

Click to read the study in NEJM

Relevant Reading: Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

In-depth [randomized clinical trial]:  This trial was a phase 2, parallel-group randomized control trial conducted across 38 sites in six European countries between 2012 and 2014. Eligible patients who had screening CMV DNA levels between 1,000 to 100,000 copes per mm in their blood or plasma were randomized in a 1:1:1:1 ratio to receive either oral maribavir (dosed at 400mg, 800mg or 1200mg twice daily) or valganciclovir at a dose of 900mg twice daily for 3 weeks, followed by 900mg once daily. All treatment was given for up to 12 weeks. The primary safety endpoint of this study was the occurrence of adverse events among patients taking maribavir versus valganciclovir. The primary efficacy endpoint was the percentage of patients who had a response to treatment defined as undetectable CMV DNA in plasma within 3 or 6 weeks of treatment. There were 161 patients who underwent randomization, and 159 patients who received treatment and were included in the intention-to treat analysis (400mg maribavir n=40; 800mg maribavir n=40, 1200mg maribavir n=39; valganciclovir n=40). There were 72 of 117 patients randomized to receive maribavir who had a response to treatment within 3 weeks (62%; 95% CI: 52 to 70) compared to 22 of 39 patients in the valganciclovir group (56%, 95% CI: 40 to 72; RR 1.12; 95% CI: 0.84 to 1.49). At 6 weeks the response rate in the maribavir group increased to 79% (95% CI 70 to 86), and to 67% in the valganciclovir group (95% CI: 50 to 80; RR 1.20, 95% CI: 0.95 to 1.51). There was a higher incidence of adverse events reported among patients in the maribavir group (52/119=42%) compared to the valganciclovir group (13/40=32%). The most common adverse event reported in the maribavir group was dysgeusia. Gastrointestinal symptoms such as nausea, vomiting and diarrhea were also more common among the maribavir group. Neutropenia was notably less common in the maribavir group as compared to the valganciclovir group.

RELATED REPORTS

#VisualAbstract: Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation

Postnatal cytolomegalovirus infection not linked to impaired motor development

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: cytomegalovirus (CMV)maribavirselective benzimidazole ribosidevalganciclovir
Previous Post

Quick Take: Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer

Next Post

Quick Take: Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging

RelatedReports

#VisualAbstract: Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation
StudyGraphics

#VisualAbstract: Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation

October 27, 2019
Postnatal cytolomegalovirus infection not linked to impaired motor development
Infectious Disease

Postnatal cytolomegalovirus infection not linked to impaired motor development

January 12, 2018
Next Post

Quick Take: Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging

Beta-blockers associated with worse outcomes in non-cardiac perioperative settings

Quick Take: Sex-Based Disparities in the Hourly Earnings of Surgeons in the Fee-for-Service System in Ontario, Canada

California’s cystic fibrosis newborn screening model is highly effective

Quick Take: Maternal Exposure to Intimate Partner Violence and Breastfeeding Practices in 51 Low-Income and Middle-Income Countries

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.